OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed

Fonds de solidarité FTQ is a private equity and venture capital firm specializing in investments in start-ups, early venture, mergers, business acquisitions, management buyouts, market development project or a buyout, financing for new programs, organic growth and cash flow, growth and expansion financings, development capital, business succession, financial restructuring, business transition financing, family and non-family buyout, consolidations, turnaround, and leveraged management buyouts. It also invests in new markets, product and business line developments, market diversification, interim financings, new product marketing, additional working capital, purchase of tangible and intangible assets, equipment modernization, equipment purchases or upgrades, and integrator projects. The firm has regional funds that do not invest in retail, real estate, farming, biotechnology, and financial services.  Fonds de solidarité FTQ invests in small and medium-sized businesses. It typically invests in export projects, forest products, productivity improvement, natural resources, aerospace, agri-food, wood, pulp and paper, chemicals, construction and construction materials, printing, transportation equipment and automobiles, transportation services, furniture and fixtures, combinatorial chemistry and other lead generating technologies, mining and exploration, social economy, textiles, plastics, life sciences, business services, telecommunications, distribution and consumer goods, environment, equipment and machinery, financial services, information and communication technology, metal products, recreational tourism, and culture sectors.  Within the culture sector, Fonds de solidarité FTQ seeks to invest in pre-production and creative projects, production projects, infrastructures and services, post-production projects, distribution, and broadcasting and multiplatform broadcasting. Within the environment sector, it invests in waste management and energy conversion for residual waste; air treatment and reduction of greenhouse gas emissions; processes to reduce industrial energy and water consumption; water treatment; and soil rehabilitation and decontamination (metals and organic compounds).  Within the life sciences sector, Fonds de solidarité FTQ focuses on services for the biopharmaceutical industry; nutraceuticals and cosmeceuticals; diagnostics and medical supplies and equipment; biopharmaceuticals and generic drugs; biotechnology, and animal health. Within the tourism sector, it focuses on urban tourism, nature tourism, resort type tourism, and local tourism for Quebecers, and in the textiles sector it invests in companies engaged in development and production of specialty textiles as well as development of industrial applications for the construction, transportation, health and safety, and work apparel industries.  Fonds de solidarité FTQ prefers to invest in Quebec and in companies impacting the Québec economy. It focuses on investing in the following regions- Abitibi –Témiscamingue, Bas Saint Laurent, Chaudière-Appalaches, Côte-Nord, Estrie, Gaspésie Îles-de-la-Madeleine, Lanaudière, Laurentides, Laval, Mauricie - Centre-du-Québec, Montérégie, Nord-du-Québec, Outaouais, and Saguenay-Lac-St-Jean.  Fonds de solidarité FTQ seeks to invest in projects of $3 million or more and also provides loans of up to $ 2 million. It invests in companies in business succession sector having minimum capitalization of $500,000 and EBITDA of over $35.5 million in case of majority interest; equipment and machinery sector with average investment in excess of $3 million; environment sector with funding needs of more than $500000; financial services sector having net assets between $20 million and $50 million in equity; metal products sector having annual sales of over $5 million and financing needs of at least $2 million; and printing sector having investment needs of over $1 million.  In the information technology sector, Fonds de solidarité FTQ seeks to invest $2 million as initial investments while total investments can be more than $10 million. It invests in the form of equity financing (common or preferred shares) and unsecured debt requiring no collateral (debenture).  Fonds de solidarité FTQ can take both a minority interest including an equity stake of up to 49 percent as well a majority interest in its portfolio companies in case of business succession financing. It seeks a minority stake for the portfolio companies in the equipment and machinery sector. It typically holds its investments for a period of five to ten years in case of equity financing and for more than ten years in case of business succession financing.  Fonds de solidarité FTQ began operation on June 23, 1983. It has its headquarters in Montreal in Canada with additional offices in the same city and Quebec in the same country.

Fonds de solidarité FTQ

Investissement Québec offers a range of financing solutions to SMEs and large companies. Investissement Québec partners in consulting and financing to support their client's expansion project in Québec. They offer the combined advantages of financial institutions and economic development agencies.

Investissement Quebec

Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies. The firm has a diverse institutional client base comprised of corporate and public pensions, endowments, foundations, sub-advisory, family offices, wealth managers, and financial advisors, globally. Driehaus is a performance-oriented investment management boutique that emphasizes integrity, transparency, and the alignment of the firm’s interests with its clients. The firm was founded in 1982 and is headquartered in Chicago, Illinois.

Driehaus Capital Management

With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.

Lumira Ventures

Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Amplitude Venture Capital

BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. The company helps create and develop strong Canadian businesses through financing, consulting services and securitization, with a focus on small and medium-sized enterprises. BDC Venture Capital has been involved in venture capital since 1975 and has to date invested in more than 400 companies involved in the areas of Life Sciences, Telecommunications, Information Technology and Advanced Technologies.

BDC Venture Capital

SilverArc Capital is an investment firm focused on healthcare.

SilverArc Capital

Bdc thrive venture invest in women-led technology companies to accelerate their growth and transform today’s markets.

Bdc Thrive venture

Congruence Therapeutics

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

<div>Based in Canada, Congruence Therapeutics is a drug discovery company specializing in the development of treatments for diseases caused by protein misfolding. The firm uses a blend of machine learning, computational chemistry, and biophysics to discover small molecules that stabilize misfolded proteins. Its proprietary platform, Revenir, plays a pivotal role in identifying and designing these molecules by analyzing the biophysical characteristics of proteins. The company is actively constructing a database of mutant proteins to broaden its research scope and address a range of rare diseases​&nbsp;</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Based in Canada, Congruence Therapeutics is a drug discovery company specializing in the development of treatments for diseases caused by protein misfolding. The firm uses a blend of machine learning, computational chemistry, and biophysics to discover small molecules that stabilize misfolded proteins. Its proprietary platform, Revenir, plays a pivotal role in identifying and designing these molecules by analyzing the biophysical characteristics of proteins. The company is actively constructing a database of mutant proteins to broaden its research scope and address a range of rare diseases​&nbsp;
 
 
 Funding and financials
 
 
 In March 2023, Congruence Therapeutics raised 
 <a href="https://sp-edge.com/updates/16874">
 USD 15 million
 </a>
 in an extended Series A funding round, bringing the total Series A funds to USD 65 million (the previous Series A round closed in February 2022). The proceeds were directed toward further developing the company&rsquo;s Revenir platform and advancing its therapeutic programs toward the clinic.
 
</div>

<div>
 
 e-Therapeutics is a UK-based company specializing in drug discovery and development. It leverages computational biology to expedite the drug discovery process, particularly in RNA interference (RNAi) medicines. The company's approach integrates network analysis, machine learning, AI, data mining, and optimization into its proprietary databases and computational tools to identify and develop therapies.&nbsp;
 
 
 The company utilizes two platforms: 1) The HepNet Computational Platform, which is an in-silico (performed via computer simulation) laboratory that allows users to conduct hypotheses, phenotypic screening, and the identification and prioritization of novel therapeutic targets, and 2) the GalOmic RNAi Platform that enables highly specific silencing of gene expression and specializes in the development of RNAi therapies.
 
 
 Further, it has four drug candidates in the pipeline, namely 1) ETX-312 to treat metabolic dysfunction-associated steatohepatitis (MASH), 2) ETX-407 to treat dry age-related macular degeneration (dAMD), 3) ETX-148 to treat pan-haemophilia, and 4) ETX-291 to treat a broad spectrum of cardiometabolic diseases.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s customers include several pharmaceutical companies to develop therapies using its proprietary platforms. These include partnerships with 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/e-therapeutics-signs-research-collaboration-agreement-novo-nordisk/">
 Novo Nordisk
 </a>
 (December 2018), 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/collaboration-galapagos-discover-new-therapeutic-strategies-treatment-idiopathic-pulmonary-fibrosis-and-other-fibrotic-condition/">
 Galapagos
 </a>
 (June 2020), and 
 <a href="https://www.etherapeutics.co.uk/news-and-media/press-releases/immuno-oncology-research-collaboration-iteos-therapeutics/">
 iTeos Therapeutics 
 </a>
 (April 2022). It is also working with another undisclosed top-five pharma company in a specific area of neurodegeneration.&nbsp;
 
 
 Further in May 2018, the company partnered with C4X Discovery to identify new pathophysiological mechanisms in Parkinson&rsquo;s disease.&nbsp;
 
 
 Funding and financials
 
 
 In 2007, the company was listed on the Alternative Investment Market, the London Stock Exchange&rsquo;s public market for small and medium-sized growth companies, under the ticker symbol &ldquo;ETX&rdquo;. Further in 
 <a href="https://sp-edge.com/updates/13462">
 September 2022
 </a>
 , the company raised GBP 13.5 million (USD 15.1 million) from funds managed by institutional investor M&amp;G Investment Management Limited via the subscription of new ordinary shares. The funds were expected to be used for the company's growth initiatives.
 
</div>

eTherapeutics

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

<div>
 
 Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris&rsquo;s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.
 
</div>

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Congruence Therapeutics

AI Drug Discovery

Key stats

Recent Updates

Congruence Therapeutics raises USD 15 million in extended Series A

Congruence Therapeutics raises USD 50 million Series A

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless